AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).
elbion (formerly ASTA Medica) and GlaxoSmithKline are developing an inhaled formulation of AWD-12-281 for the potential treatment of chronic obstructive pulmonary disease (COPD). By May 2005, phase II trials of this 5-hydroxyindole PDE4 inhibitor for COPD were ongoing.
Gutke
Hans-Jürgen
HJ
Synovo GmbH, Paul Ehrlich Strasse 15, D-72076 Tubingen, Germany.
Guse
Jan-Hinrich
JH
Khobzaoui
Moussa
M
Renukappa-Gutke
Thejavathi
T
Burnet
Michael
M
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000280:Administration, Inhalation; D000287:Administration, Topical; D000577:Amides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000631:Aminopyridines / Q000737:chemistry; D000818:Animals; D001549:Benzamides / Q000737:chemistry; D002986:Clinical Trials as Topic; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D003521:Cyclopropanes / Q000737:chemistry; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy; D008070:Lipopolysaccharides; D010047:Ovalbumin; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012140:Respiratory Tract Diseases / Q000139:chemically induced / Q000188:drug therapy; D013329:Structure-Activity Relationship
C470045:AWD 12-281; D000577:Amides; D000631:Aminopyridines; D001549:Benzamides; D003521:Cyclopropanes; D007211:Indoles; D008070:Lipopolysaccharides; D010726:Phosphodiesterase Inhibitors; C424423:Roflumilast; D010047:Ovalbumin; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4